Copyright
        ©The Author(s) 2023.
    
    
        World J Gastroenterol. Jan 14, 2023; 29(2): 390-409
Published online Jan 14, 2023. doi: 10.3748/wjg.v29.i2.390
Published online Jan 14, 2023. doi: 10.3748/wjg.v29.i2.390
		Figure 1 Therapeutic regimens recommended by Maastricht V/Florence consensus report as first-line and second-line treatment.
		
			 PPI: Proton pump inhibitor.
		
	
		Figure 2 Preferred Reporting Items for Systematic reviews and Meta-Analyzes flow diagram.
		
			 H. pylori: Helicobacter pylori.
		
	
		Figure 3 Third-line triple therapy eradication rates.
		
			 A: Triple therapy as third line (per protocol); B: Triple therapy as third line (intention to treat).
		
	
		Figure 4 Triple therapy eradication rates as rescue treatment.
		
			 A: Triple therapy as rescue treatment (per protocol); B: Triple therapy as rescue treatment (intention to treat).
		
	
		Figure 5 Third-line quadruple therapy eradication rates.
		
			 A: Quadruple therapy as third-line treatment (per protocol); B: Quadruple therapy as third-line treatment (intention to treat). BQT: Bismuth quadruple therapy; N-BQT: Non-bismuth quadruple therapy.
		
	
		Figure 6 Quadruple therapy eradication rates as rescue treatment.
		
			 A: Quadruple therapy as rescue treatment (per protocol); B: Quadruple therapy as rescue treatment (intention to treat). BQT: Bismuth quadruple therapy; N-BQT: Non-bismuth quadruple therapy.
		
	
		Figure 7 Recommendation diagram.
		
			
		
	
- Citation: de Moraes Andrade PV, Monteiro YM, Chehter EZ. Third-line and rescue therapy for refractory Helicobacter pylori infection: A systematic review. World J Gastroenterol 2023; 29(2): 390-409
- URL: https://www.wjgnet.com/1007-9327/full/v29/i2/390.htm
- DOI: https://dx.doi.org/10.3748/wjg.v29.i2.390

 
         
                         
                 
                 
                 
                 
                 
                         
                         
                         
                         
			 
			 
			 
			 
			 
			